Author Archives: admin
Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post Procedural Inflammatory and Pain Responses
The first patient undergoing wisdom tooth extraction has been dosed with HT-6184 to evaluate its effect on post-procedure diagnostic biomarkers of inflammation and pain, as well as to evaluate its safety and tolerability. LEHI, Utah, Feb. 15, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, […]
Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System
New guidance system marks significant advancement in breast cancer care, targeting tumor location in multiple dimensions for precise excision and successful surgeries SOUTH JORDAN, Utah, Feb. 15, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, has received US Food and Drug Administration (FDA) 501(k) clearance for the […]
Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for KidneyIntelX and kidneyintelX.dkd
LONDON and SALT LAKE CITY, February 9, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on February 8, 2024 the Centers for Medicare and Medicaid Services (“CMS”) published a draft Local Coverage Determination (“LCD”) for the Company’s KidneyIntelX and kidneyintelX.dkd testing. The draft LCD can be accessed at https://www.cms.gov/medicare-coverage-database/. The established Medicare price […]
Utah Legislative Recap, Feb. 9, 2024
Funding Requests Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry. BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create […]
2024 Life Sciences Day on the Hill Recap
Utah’s vibrant life sciences industry was on full display February 7 as part of BioUtah’s “Life Sciences Day on the Hill”. The event, a collarboration with the Governor’s Office of Economic Opportunity, (GOEO) was held at the state capitol. 29 companies exhibited their innovative technologies in the capitol rotunda, which provided legislators the opportunity to […]
Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics
Funds will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia’s first-in-class NLRP3/NEK7 inflammasome inhibitor, and advancing additional programs into the clinic. LEHI, Utah, Jan. 31, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the completion […]
Halia Therapeutics Dosed its First Patient in Phase 2a Clinical Trial of HT-6184, a First-in-Class NLRP3-Inhibitor, for the Treatment of Lower-Risk Myelodysplastic Syndromes
LEHI, Utah /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the dosing of the first patient in Phase 2a clinical trial evaluating its lead candidate, HT-6184, for the treatment of lower-risk myelodysplastic syndromes (LR-MDS). HT-6184 is a selective and orally bioavailable first-in-class […]
RxCell Announces $4.6M Investment from DMR Global Venture and Regenosis, Plans for Second Raise of $15M for IND Testing in Q4 2023
SINGAPORE–(BUSINESS WIRE)–RxCell, a pioneering biotech company focusing on cellular therapeutics for age-related diseases, today proudly announces a $4,600,000 investment commitment from DMR Global Venture LLC and Regenosis. Building on the strength of collaboration with National University of Singapore, this fresh investment accentuates RxCell’s resolute drive to revolutionize age-related disease treatment. “We’re thrilled to align with […]
Culmination Bio Raises $10M From Amgen Ventures and Merck Global Health Innovation Fund to Bring Longitudinal Health Data to Biopharma
Culmination Bio has over 40 years of biospecimen data and counting, paired with clinical data from patient EHRs, making recruitment for pharmaceutical research almost instantaneous. St. George, Utah — (November 30, 2023) — Culmination Bio, a company building the largest disease-agnostic patient data intelligence platform, today announced a $10 million investment from Merck Global Health […]
SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK – ENROLLMENT TO STOP DUE TO SUCCESS
SALT LAKE CITY, Dec. 6, 2023 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal […]
2023 Utah Life Sciences Summit Recap and Gallery
BioUtah yesterday held its 2023 Utah Life Sciences Summit, presented by Mayer Brown. Every year, the Summit is the largest gathering of Utah’s life sciences industry. This year was no exception. Following welcome remarks from Gov. Spencer Cox, a distinguished line-up of top executives addressed a packed house. Keynote speaker, Joseph Smith, chief scientific officer […]
2023 BioUtah Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
SALT LAKE CITY – November 3, 2023 – BioUtah today announced the winners of its 2023 Life Sciences Awards. Five awards will be presented during the 2023 Mayer Brown Utah Life Sciences Summit Nov. 9 at the Salt Palace, in Salt Lake City. BioUtah’s annual awards recognize leaders, innovators and entrepreneurs who have made significant […]
